Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
NCT07123090Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sasanlimab, palbociclib, axitinib in renal cell carcinoma (RCC). Started Nov 2025; status: recruiting.
02
Drugs
sasanlimabpalbociclibaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07123090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123090.